Clinical outcome in patients with peripheral artery disease. Results from a prospective registry (FRENA)

Monréal, Manuel; Álvarez, Lorenzo Ramón; Vilaseca, Blanca; Coll, Ramón; Suárez, Carmen; Toril, Jesús; Sanclemente, Carmen

doi:10.1016/j.ejim.2007.09.003

Cited by 32 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 However, both vascular mortality and total mortality in the 10-year period were well below those described for the natural history and also in studies on secondary prevention measures in claudicants. [17][18][19][20][21] This needs to be discussed in the context of the inclusion criteria chosen for the study: none of the study patients had a vascular or serious nonvascular comorbidity at the start of the study and renal failure was an exclusion criterion. Intermittent claudication symptoms had not been present for longer than 12 months.…”

Section: Discussionmentioning

confidence: 99%

The Possible Risk of Cancer in Claudicants

et al. 2011

View full text Add to dashboard Cite

The aim of this study was to select a group of patients who had mild intermittent claudication and were undergoing secondary prevention measures, and record all vascular and non-vascular events over a 10-year follow-up. A total of 534 events were recorded in 109 claudicants. 25.7% of the claudicants died, 39% of them due to vascular events, 36% from cancer and 25% from other causes. 17 of the 20 cancer cases could be classified as related to smoking. Cancer occurred relatively early in the study, within the first five years, while severe vascular events occurred mainly during later periods. A clear transformation occurred in the outcome of the claudicants. Mortality was equally attributable to vascular and cancer-related comorbidities. In conclusion, the improvement of vascular outcomes due to secondary prevention measures and technological advances in the management of acute vascular events may result in a relative increase in cancer incidence and deaths.

show abstract

Section: Discussionmentioning

confidence: 99%

The Possible Risk of Cancer in Claudicants

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Treatment of PAD includes anticoagulants and antiplatelet drugs, percutaneous transluminal angioplasty, and bypass surgery. However, the prognosis for patients with PAD still remains poor, and amputation of the lower extremities is often required [2]. Several types of stem cells have been used for therapeutic neovascularization, including the bone marrow-derived mesenchymal stem cells (MSCs), which have attracted a great attention from investigators because of their plasticity and availability[3].…”

Section: Introductionmentioning

confidence: 99%

Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation

Zhang

et al. 2010

J Biomed Sci

View full text Add to dashboard Cite

ObjectivesWe postulated that combining high-dose simvastatin with bone marrow derived-mesenchymal stem cells (MSCs) delivery may give better prognosis in a mouse hindlimb ischemia model.MethodsMouse hindlimb ischemia model was established by ligating the right femoral artery. Animals were grouped (n = 10) to receive local injection of saline without cells (control and simvastatin groups) or with 5 × 106 MSCs (MSCs group).Animals received either simvastatin (20 mg/kg/d, simvastatin and combination groups) or saline(control and MSCs group) gavages for continual 21 days. The blood flow was assessed by laser Doppler imaging at day 0,10 and 21 after surgery, respectively. Ischemic muscle was harvested for immunohistological assessments and for VEGF protein detection using western blot assay at 21 days post-surgery. In vitro, MSCs viability was measured by MTT and flow cytometry following culture in serum-free medium for 24 h with or without simvastatin. Release of VEGF by MSCs incubated with different doses of simvastatin was assayed using ELISA.ResultsCombined treatment with simvastatin and MSCs induced a significant improvement in blood reperfusion, a notable increase in capillary density, a highest level of VEGF protein and a significant decrease in muscle cell apoptosis compared with other groups. In vitro, simvastatin inhibited MSCs apoptosis and increased VEGF release by MSCs.ConclusionsCombination therapy with high-dose simvastatin and bone marrow-derived MSCs would augment functional neovascularization in a mouse model of hindlimb ischemia.

show abstract

“…Therefore, patients undergoing carotid endarterectomy (CEA) may harbor disease in several arterial beds. Patients with arterial disease have been shown to have decreased life expectancy, 1 increased cardiovascular mortality, 2 and elevated rates of chronic kidney disease and functional impairment. 3 The beneficial effects of statins have been well documented in coronary artery disease (CAD) prevention, 4 but patients with peripheral arterial disease (PAD) remain undertreated.…”

Section: Introductionmentioning

confidence: 99%

Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy

et al. 2009

View full text Add to dashboard Cite

Secondary prevention of cardiovascular disease after carotid endarterectomy should include management of low-density lipoprotein (LDL) levels, but increased LDL levels are undertreated in these patients. We examined trends in statin use and LDL goal achievement in veterans undergoing carotid endarterectomy (CEA), a medically high-risk group with high rates of cardiovascular morbidity and mortality. The records of all CEA performed between 1995 and 2005 in the Connecticut Veterans' Affairs (VA) hospital were reviewed. Kaplan-Meier analysis was used to analyze long-term outcomes. ANOVA was used for comparisons between groups. A total of 309 CEA procedures were performed in 298 patients. The mean follow-up was 4.1 years. Statin use increased over time (12% in 1995, 84% in 2005) and mean LDL levels decreased (105 mg/dl in 1997, 90 mg/dl in 2007). The number of patients achieving LDL goals of 100 mg/dl or 70 mg/dl increased. Mean HDL levels decreased (53 mg/dl in 1997 and 38 mg/dl in 2007). Patients with three or more comorbid medical conditions were more likely to achieve LDL goals. At 12 years, freedom from stroke was 91%, freedom from myocardial infarction was 46% and survival was 12%. In conclusion, over the last decade, among patients who have undergone CEA, statin use has increased and LDL levels have improved.

show abstract

Clinical outcome in patients with peripheral artery disease. Results from a prospective registry (FRENA)

Cited by 32 publications

References 14 publications

The Possible Risk of Cancer in Claudicants

The Possible Risk of Cancer in Claudicants

Augmentation of neovascularization in murine hindlimb ischemia by combined therapy with simvastatin and bone marrow-derived mesenchymal stem cells transplantation

Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy

Contact Info

Product

Resources

About